Todos Med (OTCMKTS:TOMDF) and Aclarion (NASDAQ:ACON) Head-To-Head Survey

Aclarion (NASDAQ:ACON) and Todos Med (OTCMKTS:TOMDF) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Institutional and Insider Ownership

7.5% of Aclarion shares are held by institutional investors. 0.8% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Aclarion and Todos Med, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	0	0	0	1.00
Todos Med	0	0	0	0	0.00

Given Todos Med’s higher probable upside, analysts clearly believe Todos Med is more favorable than Aclarion.

Risk & Volatility

Aclarion has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Todos Med has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500.

Profitability

This table compares Aclarion and Todos Med’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-9,517.11%	-52.31%	-49.79%
Todos Med	N/A	N/A	N/A

Earnings and Valuation

This table compares Aclarion and Todos Med”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80,000.00	32.51	-$7.23 million	($17.01)	-0.18
Todos Med	N/A	N/A	N/A	N/A	N/A

Todos Med has lower revenue, but higher earnings than Aclarion.

Summary

Aclarion beats Todos Med on 5 of the 9 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About Todos Med

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.